Sarah E Pinder
Affiliation: University of Nottingham
- The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH)--current definitions and classificationSarah E Pinder
University of Nottingham and Nottingham City Hospital NSH Trust, Nottingham, UK
Breast Cancer Res 5:254-7. 2003..The current definitions, histological features, and system of classification of ADH and DCIS are described in this manuscript...
- Lobular in situ neoplasia and columnar cell lesions: diagnosis in breast core biopsies and implications for managementSarah E Pinder
Department of Histopathology, Addenbrooke s Hospital, Cambridge, United Kingdom
Pathology 39:208-16. 2007..This review provides an update on the histological diagnosis of lobular neoplasia and columnar cell lesions and outlines recent clinico-pathological and molecular findings with discussion on clinical management...
- Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breastR R Millis
Hedley Atkins Cancer Research UK Breast Pathology Laboratory, Guy s Hospital, London SE1 9RT, UK
Br J Cancer 90:1538-42. 2004..This is in agreement with immunohistochemical and molecular data indicating that low-grade and high-grade mammary carcinomas are quite different lesions...
- Successful management of elderly breast cancer patients treated without radiotherapyKalliope Valassiadou
Division of Breast Surgery, University of Nottingham, Nottingham, UK
World J Surg Oncol 5:62. 2007..The addition of RT to surgery might constitute an imposition to such patients due to age-related factors. The aim of this study was to assess the efficacy of BCS without adjuvant RT in this group of patients...
- Macroscopic handling and reporting of breast cancer specimens pre- and post-neoadjuvant chemotherapy treatment: review of pathological issues and suggested approachesSarah E Pinder
Research Oncology, Division of Cancer Studies, King s College London, Guy s Hospital, London, UK
Histopathology 67:279-93. 2015..In this manuscript we review these issues and describe some practical approaches to handling and reporting these samples in the routine histopathology laboratory. ..
- Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic valueShalaka Joshi
Department of Research Oncology, King s College London, Faculty of Life Science and Medicine, Division of Cancer Studies, Bermondsey Wing, Guy s Hospital, London, UK
BMC Cancer 15:546. 2015..Even for Ki67, one of the most widely-studied markers, disagreements over the optimal cutoff exist. Improvements in digital microscopy may provide new avenues to standardise and make data more reproducible...
- Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)?Zahra Madjd
CRC Academic Department of Clinical Oncology, Nottingham City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK
Cancer Immunol Immunother 54:149-56. 2005..Breast carcinomas are reported to consistently express CD46...
- Comparison of margin assessment by radial and shave sections in wide local excision specimens for invasive carcinoma of the breastZsolt Hodi
Department of Histopathology, Nottingham University Hospitals, Nottingham, UK
Histopathology 56:573-80. 2010..Shave sections assess a larger surface area of margin than radial sections. The aim was to assess the value of additional shave sections of the margin...
- Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval timeJennifer C Melvin
King s College London, Division of Cancer Studies, Cancer Epidemiology Group, Guy s Hospital, 3rd Floor, Bermondsey Wing, London SE1 9RT, UK
Br J Cancer 114:88-95. 2016..We aimed to improve our understanding of the impact of LR on prognosis by examining a large cohort of patients treated at Guy's and St Thomas' NHS Foundation Trust...
- Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluationSarah E Pinder
Breast Research Pathology, Research Oncology, Division of Cancer Studies, King s College London, Guy s Hospital, London, UK
Mod Pathol 23:S8-13. 2010..No biomarkers have been convincingly shown, and validated, to predict the behavior of DCIS till date...
- Selective use of post-mastectomy flap irradiation in high-risk breast cancer patientsKristjan S Asgeirsson
The Nottingham Breast Institute, Nottingham City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK
Breast 14:298-303. 2005..The chest wall recurrence rate was 2.7% in those treated with radiotherapy. A low rate of local recurrence has been achieved with selective use of mastectomy flap radiotherapy...
- The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an exampleSarah E Pinder
Research Oncology, Division of Cancer Studies, King s College London, Guy s Hospital, Great Maze Pond, London, UK
J Clin Pathol 66:169-77. 2013..We make some suggestions regarding these challenges, and propose a checklist of features that should be considered in order to stimulate debate and improve the quality of data produced by TMA analysis...
- Challenges in the management of pleomorphic lobular carcinoma in situ of the breastYazan A Masannat
Guy s Hospital, Guy s and St Thomas NHS Foundation Trust, Great Maze Pond, London SE1 9RT, UK
Breast 22:194-6. 2013..Pleomorphic Lobular Carcinoma in Situ (PLCIS) is a pathological variant of Lobular Carcinoma in Situ (LCIS) with distinct features. Since first described over a decade ago there are only few papers published about this condition...
- Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profilesPatrycja Gazinska
Breakthrough Breast Cancer Research Unit, King s College London, School of Medicine, Division of Cancer Studies, Bermondsey Wing, Guy s Hospital, London SE1 9RT, UK
Mod Pathol 26:955-66. 2013..This incomplete overlap of cases emphasizes the need for consistent or new approaches to improve precise identification. ..
- Updated UK Recommendations for HER2 assessment in breast cancerEmad A Rakha
Department of Pathology, University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, UK
J Clin Pathol 68:93-9. 2015..Pathologists, oncologists and surgeons involved in test interpretation and clinical use should adhere to published guidelines and maintain accurate performance and consistent interpretation of test results. ..
- Diagnostic, predictive and prognostic breast pathology. EditorialSarah E Pinder
Professor of Breast Pathology, Kings College London, Department of Academic Oncology, 3rd Floor Thomas Guy House, Guy s Hospital, St Thomas Street, London SE1 9RT, UK
Histopathology 52:1-2. 2008
- Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinomaGavin C Harris
Department of Histopathology, Nottingham City Hospital, UK
Am J Surg Pathol 27:11-5. 2003..However, in those patients in whom preoperative assessment of prognostic factors is most likely to be beneficial, i.e., those with grade 3 carcinomas, a high level of agreement was achieved in this large study...
- Interobserver reproducibility in the diagnosis of flat epithelial atypia of the breastFrances P O'Malley
Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada
Mod Pathol 19:172-9. 2006..1-97.4%), than for determining its presence (90.4%: 95% CI, 79.9-96.7%). We conclude that the diagnosis of FEA and its distinction from CCLs without atypia is highly reproducible with the use of available diagnostic criteria...
- Reproducibility of cancer diagnosis using hairKeith D Rogers
Int J Cancer 118:1060; author reply 1061-2. 2006
- Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progressionMichael A Gonzalez
Medical Research Council Cancer Cell Unit, Hutchison MRC Research Centre, Hills Road, Cambridge CB2 2XZ, UK
J Pathol 204:121-30. 2004..It is suggested that this explains its unexpected value as a prognostic marker in breast cancer...
- Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysisThomas C Putti
Department of Pathology, National University of Singapore, Singapore
Mod Pathol 18:26-35. 2005....
- Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosisEmad A Rakha
Department of Histopathology, Nottingham City Hospital, University of Nottingham, UK
J Pathol 203:754-61. 2004..E2F-4 appears to have an oncogenic role rather than a tumour suppressor role in breast carcinogenesis and, hence, it is not the gene targeted by 16q22.1 loss in breast carcinoma...
- Expression of luminal and basal cytokeratins in human breast carcinomaDalia M Abd El-Rehim
Department of Histopathology, Breast Unit, Nottingham City Hospital NHS Trust and University of Nottingham, UK
J Pathol 203:661-71. 2004..These findings provide further evidence that breast cancer has distinct differentiation subclasses that have both biological and clinical relevance...
- Is mammographic spiculation an independent, good prognostic factor in screening-detected invasive breast cancer?Andrew J Evans
Breast Institute, Nottingham International Breast Education Center and Nottingham City Hospital, Hucknall Rd, Nottingham NG5 1PB, United Kingdom
AJR Am J Roentgenol 187:1377-80. 2006..The aim of this study was to review the prognostic significance of pathologic and radiologic factors for screening-detected invasive breast cancers of any size...
- Loss of CD55 is associated with aggressive breast tumorsZahra Madjd
Cancer Research UK Academic Unit of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, United Kingdom
Clin Cancer Res 10:2797-803. 2004..CD55 is overexpressed on some tumor cell lines, and in colorectal carcinomas, it has been shown to be an indicator of poor prognostic...
- Epidermal growth factor receptor status in operable invasive breast cancer: is it of any prognostic value?Raj S Rampaul
Clin Cancer Res 10:2578. 2004
- Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancerMichael A Gonzalez
Medical Research Council Cancer Cell Unit, Hutchison Medical Research Council Research Centre, Hills Rd, Cambridge CB2 2XZ, United Kingdom
J Clin Oncol 21:4306-13. 2003..To test the hypothesis that prognostic information in breast cancer may be derived from an accurate assessment of epithelial cell cycle entry, as indicated by expression of minichromosome maintenance (MCM) proteins...
- An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breastBarbara Dunne
Department of Pathology, City Hospital, Nottingham, United Kingdom
Hum Pathol 34:1009-15. 2003..In our hands, 34betaE12 was the CK most frequently expressed in sarcomatoid areas in MSCs...
- High-resolution analysis of 16q22.1 in breast carcinoma using DNA amplifiable probes (multiplex amplifiable probe hybridization technique) and immunohistochemistryEmad A Rakha
The Breast Unit, Department of Histopathology, Nottingham City Hospital, University of Nottingham, United Kingdom
Int J Cancer 114:720-9. 2005..Although our results support E-cadherin as the TSG in invasive lobular carcinoma, they argue against the candidacy of E2F-4, CTCF, TRF2, P-cadherin, Ksp-cadherin and VE-cadherin as TSGs in breast cancer...
- Upregulation of MICA on high-grade invasive operable breast carcinomaZahra Madjd
Academic Department of Clinical Oncology, Institute of Infections, Immunity and Inflammation, University of Nottingham, City Hospital, Nottingham, NG5 1PB, United Kingdom
Cancer Immun 7:17. 2007..Our results suggest that induced expression of MICA may be an indicator of poor prognosis in breast carcinoma and is indicative of a tumour environment that has undergone stresses such as apoptosis, necrosis, or hypoxia...
- High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancerSuet F Chin
Breast Cancer Functional Genomics, Cancer Research UK Cambridge Research Institute and Department of Oncology University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
Genome Biol 8:R215. 2007..To date, most genome-wide array comparative genomic hybridization studies have used tumor panels of relatively large tumor size and high Nottingham Prognostic Index (NPI) that are not as representative of breast cancer demographics...
- Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic IndexGrace M Callagy
Cancer Genomics Program, Department of Oncology, Hutchison Medical Research Council Research Centre, University of Cambridge, United Kingdom
Clin Cancer Res 12:2468-75. 2006..We validated the results in an independent series...
- Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysisPeter T Simpson
Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK
Am J Surg Pathol 29:734-46. 2005..These data further support the hypothesis that CCLs are a nonobligate, intermediary step in the development of some forms of low grade in situ and invasive carcinoma...
- A consensus prognostic gene expression classifier for ER positive breast cancerAndrew E Teschendorff
Cancer Genomics Program, Department of Oncology, University of Cambridge, Hutchison MRC Research Center, Hills Road, Cambridge CB2 2XZ, UK
Genome Biol 7:R101. 2006..A consensus prognostic gene expression classifier is still elusive in heterogeneous diseases such as breast cancer...
- MYC amplification in breast cancer: a chromogenic in situ hybridisation studyS Maria Rodriguez-Pinilla
The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
J Clin Pathol 60:1017-23. 2007....
- Non-operative breast pathology: lobular neoplasiaJorge S Reis-Filho
The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
J Clin Pathol 60:1321-7. 2007..Furthermore, the current recommendations for the management of lobular neoplasia diagnosed on core needle biopsies proposed in the National Health Service Breast Cancer Screening guidelines are discussed...
- High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analysesDalia M Abd El-Rehim
Department of Histopathology, The Breast Unit, Nottingham City Hospital NHS Trust and University of Nottingham, Nottingham, United Kingdom
Int J Cancer 116:340-50. 2005..These observations could form the basis of revision of existing traditional classification systems for breast cancer...
- Total loss of MHC class I is an independent indicator of good prognosis in breast cancerZahra Madjd
Cancer Research UK Academic Unit of Clinical Oncology, Nottingham City Hospital, United Kingdom
Int J Cancer 117:248-55. 2005..001), tumour grade (p = 0.005) and intensity of MHC Class I light and heavy chains expression were shown to be independent prognostic factors predictive of overall survival (p-values HC10 = 0.047 and beta2m = 0.018)...
- HER2 status in breast cancer--an example of pharmacogenetic testingMark Kroese
Consultant in Public Health Medicine, Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, UK
J R Soc Med 100:326-9. 2007..Future options for the national provision of HER2 testing by the National Health Service in the UK are also discussed...
- An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancerAndrew E Teschendorff
Breast Cancer Functional Genomics Laboratory, Cancer Research UK Cambridge Research Institute and Department of Oncology, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
Genome Biol 8:R157. 2007..Reliable identification of ER-negative tumors that have a good prognosis is not yet possible...
- Non-operative breast pathologySarah E Pinder
J Clin Pathol 60:1297-9. 2007